Tech Company Financing Transactions
Galera Therapeutics Funding Round
On 2/3/2016, Galera Therapeutics landed $5 million in Series B financing from Enso Ventures.
Transaction Overview
Company Name
Announced On
2/3/2016
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series B
Investors
Enso Ventures (Sergei Petukhov)
Proceeds Purpose
The investment capital will be used to advance the Company's lead candidate GC4419 in a Phase 2b double-blind, randomized clinical trial that is currently enrolling head and neck cancer patients receiving chemoradiation therapy to prevent against oral mucositis (OM). The proceeds will also support continued development of Galera's pipeline of selective dismutase mimetics to modulate oxygen metabolic pathways.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2 West Liberty Blvd. 110
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Not Recorded
Overview
Galera Therapeutics (Nasdaq: GRTX) develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mel Sorensen
Chief Financial Officer
Joel Sussman
Chief Medical Officer
Jon Holmlund
Chief Operating Officer
Robert Beardsley
Chief Scientific Officer
Dennis Riley
VP - Bus. Development
Arthur Fratamico
VP - Bus. Development
Stephen Ross
Browse more venture capital transactions:
Prev: 2/3/2016: Tattoodo venture capital transaction
Next: 2/3/2016: OpenMethods venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs